Qilu Pharmaceutical's Lenalidomide Capsules Included in the Fifth Batch of National Negotiated Generic Drug Procurement List

On May 10, the Drug and Medical Device Centralized Procurement Division of the Guangxi Zhuang Autonomous Region Public Resource Trading Center issued a notice announcing the inclusion of generic versions of negotiated drugs in the centralized procurement program for 36 nationally negotiated drugs (Fifth Batch). The notice indicated that Qilu Pharmaceutical’s lenalidomide capsules were included, with the company’s bid price at RMB 4,580 per box.

To all medical and health institutions, manufacturers, and distributors:

Notice on Including Generic Versions of Negotiated Drugs in the Centralized Procurement of 36 National Negotiated DrugsIn accordance with the requirements of the *Notice on Including Generic Versions of Negotiated Drugs in the Centralized Procurement of 36 National Negotiated Drugs*, the generic versions of negotiated drugs that applied for inclusion in the centralized procurement of the 36 national negotiated drugs in Guangxi from March 28, 2019, to May 10, 2019, and submitted complete documentation are hereby announced (see the attachment for details). The relevant drug varieties have been integrated into the new version of the Drug Trading System and the new version of the Essential Medicine Trading System. All healthcare institutions, manufacturers, and distributors are requested to implement the results as announced in this Notice.

Pharmaceutical and Medical Device Centralized Procurement Division, Guangxi Zhuang Autonomous Region Public Resources Trading Center

May 10, 2019

Appendix: Summary Table of Generic Drugs Included in the Centralized Procurement of 36 National Negotiated Medicines (Fifth Batch)